Trial finds GSK Ebola shot is safe and provokes immune response

January 28, 2015 10:00 PM

12 0

LONDON (Reuters) - First results from a human trial of an Ebola vaccine from GlaxoSmithKline show it is safe and generates an immune response, scientists said on Wednesday, but larger trials are needed to see if it protects and if a booster is needed.

The vaccine is being developed by the U.S. National Institutes of Health (NIH) and GSK against the Zaire strain of Ebola -- the one circulating in West Africa -- and the first doses for a larger trial arrived in Liberia last week.

Read more

To category page